Business Impact of the Spread of COVID-19
First written in FY2020-Q2. 6 of 13 entries say "Materialised", first in FY2020-Q3. Latest entry: FY2023.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2023MitigatedAnnual report
「During the current consolidated fiscal year, the economic environment showed signs of normalization in social and economic activity, as the impact of the novel coronavirus disease was eased and activity by people in Japan and overseas recovered.」
Regarding the impact of COVID-19 on economic and business activity, the disclosure cites the easing of the impact of the disease and the recovery of social and economic activity. - FY2023-Q3MitigatedAnnual report
「During the first 9 months of the current consolidated fiscal year, progress was made in many regions worldwide, including Japan, toward balancing measures against the novel coronavirus disease (COVID-19) with social and economic activity, and signs of a gradual recovery in the global economy were observed.」
Regarding the impact of COVID-19 on economic activity and demand, the disclosure states that many regions worldwide made progress in balancing measures against the disease with social and economic activity, and that the economy was recovering. - FY2023-Q2MitigatedAnnual report
「During the first 6 months of the current consolidated fiscal year, restrictions on economic activity related to the novel coronavirus disease (COVID-19) were substantially eased in many regions worldwide, and the global economy as a whole was moving toward normalization.」
The disclosure states that restrictions on economic activity related to COVID-19 were eased in many regions and that the global economy was moving toward normalization. - FY2022-Q3ReframedAnnual report
「During the first 9 months of the current consolidated fiscal year, the global economy entered a recovery trend as restrictions on activities related to the novel coronavirus disease (COVID-19) were eased in most regions, except some areas. Despite the impact of China’s lockdowns, revenue was ¥6,079 million, up 9.0% year on year, driven by strong sales of diamond burs and other products in Asia, mainly in India.」
The impact of activity restrictions caused by COVID-19 has shifted from broad-based revenue declines to a combination of a global economic recovery trend and continuing effects in some regions, including China’s lockdowns. - FY2022-Q2MitigatedAnnual report
「Revenue was ¥1,339 million, up 15.7% year on year, as demand recovered in Asia and Europe due to the recovery from COVID-19.」
Demand for atraumatic-needle-related products, which had continued to decline due to COVID-19, recovered in Asia and Europe, resulting in revenue growth of 15.7% year on year. - FY2022-Q1MitigatedAnnual report
「Revenue was ¥1,339 million, up 15.7% year on year, as demand recovered in Asia and Europe due to the recovery from COVID-19.」
Against a backdrop of continued restrictions on surgeries and lower demand caused by COVID-19, the disclosure states that demand recovered in Asia and Europe as the region recovered from COVID-19, and that revenue from atraumatic-needle-related products increased 15.7% year on year. - FY2021MaterialisedAnnual report
「Meanwhile, revenue from atraumatic-needle-related products declined because product demand fell as hospital surgeries were restricted due to the impact of the novel coronavirus.」
The impact of restrictions on hospital surgeries caused by COVID-19 continues to be reflected in performance as lower product demand for atraumatic-needle-related products and lower full-year revenue. - FY2021-Q3MaterialisedAnnual report
「Meanwhile, revenue from atraumatic-needle-related products declined, affected by restrictions on hospital surgeries and other factors resulting from the impact of the novel coronavirus disease (COVID-19).」
The business impact of restrictions on hospital surgeries caused by COVID-19 continues to be reflected in performance as lower revenue from atraumatic-needle-related products. The disclosure states that higher sales in China drove revenue growth for surgical- and dental-related products. - FY2021-Q2MaterialisedAnnual report
「Meanwhile, revenue from surgical-related products and atraumatic-needle-related products declined overall, affected by restrictions on hospital surgeries and other factors resulting from the impact of the novel coronavirus disease (COVID-19).」
The business impact of COVID-19 continues to be reflected in performance this quarter as lower revenue from surgical and atraumatic-needle-related products through restrictions on hospital surgeries. - FY2021-Q1MaterialisedAnnual report
「Overall revenue declined, affected by restrictions on hospital surgeries and other factors resulting from the impact of the novel coronavirus disease (COVID-19).」
The business impact of COVID-19 continues to be reflected in performance this quarter as lower revenue from surgical and atraumatic-needle-related products through restrictions on hospital surgeries. - FY2020MaterialisedAnnual report
「Sales declined in all segments, including Surgical, Atraumatic Needles and Dental, due to restrictions on marketing activities caused by the impact of the novel coronavirus disease (COVID-19), as well as a worldwide decline in surgical procedures and medical treatments.」
The risk being monitored as of the second quarter materialized over the full year as restrictions on marketing activities, declines in surgical procedures and medical treatments, and lower sales in all 3 segments. - FY2020-Q3MaterialisedAnnual report
「Sales declined in all segments, including Surgical, Atraumatic Needles and Dental, as marketing activities were restricted by the impact of the novel coronavirus disease (COVID-19), while the number of surgical procedures and other activities was limited worldwide.」
The disclosure states that the business impact of COVID-19, which was being monitored as of the second quarter, materialized as restrictions on marketing activities, fewer surgical procedures, and declining sales in all segments. - FY2020-Q2First statedAnnual report
「The company will continue to monitor developments regarding the impact of the spread of the novel coronavirus disease (COVID-19) on its business. During the first half of the current consolidated fiscal year, overseas economies faced concerns about downside risks to the economy as a whole due in part to the spread of the novel coronavirus disease (COVID-19), as well as the potentially crisis-laden relationship and rising tensions between the United States and Iran.」
The disclosure identifies the spread of the novel coronavirus disease as a new risk requiring monitoring for its impact on the business and as a downside factor for overseas economies. It does not present specific impacts or figures relating to the infection’s effect on the company’s performance.